| 翻訳と辞書 |
| Elvitegravir ： ウィキペディア英語版 |
Elvitegravir
Elvitegravir (EVG, formerly GS-9137) is an integrase inhibitor used to treat HIV infection. It was developed〔Gilead Press Release (Phase III Clinical Trial of Elvitegravir ) July 22, 2008〕 by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008.〔Gilead Press Release (Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor ) March 22, 2008〕 The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. On September 24, 2014 the FDA approved Elvitegravir (tradename Vitekta) as a single pill formulation.〔 ("FDA Approval Bulletin" ) Accessed November 1, 2014〕
According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.〔Thaczuk, Derek and Carter, Michael. (ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents ) Aidsmap.com. 19 Sept. 2007.〕
== Medical uses ==
In the United States, elvitegravir can be obtained either as part of the combination pill Stribild or as the single pill formulation Vitekta.〔("FDA Approved Drug Listing" ) Accessed November 1, 2014〕
Vitekta is FDA approved to be used for the treatment of HIV-1 infection in adults who have previous treatment experience with antiretroviral therapy. It must be used in combination with a protease inhibitor that is coadministered with ritonavir as well as additional antiretroviral drug(s).〔 ("Vitekta Package Insert" ) Foster City, CA: Gilead Sciences, Inc.; 2014. Accessed November 1, 2014 〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Elvitegravir」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|